Novo Nordisk plans to invest DKK 650 million ($98 million) in upgrading and expanding facilities at its production site in Kalundborg, Denmark.

The facilities targeted for investment manufacture a range of products for diabetes treatments and will be rebuilt to allow for future production of products. The projects are expected to be completed in 2020.

Novo Nordisk’s production site in Kalundborg also houses production facilities for Novozymes. Established in 1969, the site today covers a total area of 1.2 million square meters. Novo Nordisk Kalundborg employs close to 3,500 people, and the 14 factories housed on the site are a cornerstone of Novo Nordisk’s global production network, which includes production for insulin and other biopharmaceutical products.

Source: Novo Nordisk